Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zocilurtatug pelitecan + atezolizumab
- Development stage
- Phase 1
- Lead developer
- Roche
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Zocilurtatug pelitecan + atezolizumab is an investigational combination therapy consisting of zocilurtatug pelitecan (formerly ZL-1310), a delta-like ligand 3 (DLL3)-targeted antibody-drug conjugate (ADC), and atezolizumab, a programmed death-ligand 1 (PD-L1)-directed checkpoint inhibitor. Zocilurtatug pelitecan delivers a novel camptothecin derivative (a topoisomerase 1 inhibitor) payload directly to DLL3-expressing tumor cells using the TMALIN platform, while atezolizumab enhances the anti-tumor immune response by blocking the PD-1/PD-L1 pathway. Developed by Zai Lab, this chemotherapy-free doublet regimen is currently in Phase 1b clinical development as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), demonstrating high objective response rates and encouraging durability.
- Other names
- ZL 1310 + atezolizumabZL-1310 + atezolizumabatezolizumab + zocilurtatug pelitecanzoci + atezolizumabzocilurtatug pelitecan and atezolizumab
02
Targets
CD80 (T-lymphocyte activation antigen CD80)DLL3 (Delta-like ligand 3)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on zocilurtatug pelitecan + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zocilurtatug pelitecan + atezolizumab.